Drugs in MeSH Category Analgesics

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	PREGABALIN	pregabalin	CAPSULE;ORAL	091224-004	Jul 19, 2019		DISCN	No	No
Apotex	PREGABALIN	pregabalin	CAPSULE;ORAL	211685-005	Jul 7, 2021		DISCN	No	No
Zydus Pharms	DULOXETINE HYDROCHLORIDE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	090728-002	Jan 8, 2014	AB	RX	No	No
Msn	PREGABALIN	pregabalin	TABLET, EXTENDED RELEASE;ORAL	213226-002	Apr 13, 2021	AB	RX	No	No
Hq Spclt Pharma	MAGNESIUM SULFATE IN PLASTIC CONTAINER	magnesium sulfate	INJECTABLE;INJECTION	207350-001	Dec 6, 2017	AP	RX	No	No

Patent Landscape Analysis: Analgesics (NLM MeSH Class)

Last updated: February 19, 2026

Summary

This report analyzes the patent landscape and market dynamics of analgesic drugs, categorized under the National Library of Medicine (NLM) MeSH (Medical Subject Headings) class "Analgesics." The analysis focuses on patent filings, expiration timelines, key therapeutic areas, and emerging trends impacting R&D and investment decisions. The opioid crisis and subsequent regulatory actions have significantly reshaped the market, driving innovation towards non-opioid alternatives and multimodal pain management strategies. Patent filings indicate a robust pipeline, particularly in areas such as neuropathic pain, inflammatory pain, and patient-specific treatments.

What is the NLM MeSH Classification "Analgesics"?

The NLM MeSH classification "Analgesics" encompasses drugs that relieve pain without causing loss of consciousness. This broad category is further subdivided to classify specific mechanisms of action and therapeutic uses. Key subheadings within "Analgesics" include:

• Analgesics, Non-Narcotic: Drugs that relieve pain and fever but do not produce dependence or tolerance. Examples include acetaminophen and NSAIDs.
• Analgesics, Opioid: Drugs that produce analgesia by interacting with opioid receptors. Examples include morphine, codeine, and fentanyl.
• Anesthetics, Local: Drugs that reversibly block nerve impulse conduction, causing loss of sensation in a specific area. Examples include lidocaine and bupivacaine.
• Antipyretics: Drugs that reduce fever. This category often overlaps with Analgesics, Non-Narcotic, as many antipyretic drugs also possess analgesic properties.
• Nerve Block: Procedures or agents used to interrupt nerve signals.
• Pain Management: Broadly covers all strategies and agents used to alleviate pain.

What are the Dominant Therapeutic Areas within Analgesic Patents?

Patent filings within the "Analgesics" MeSH class are concentrated in several key therapeutic areas, reflecting unmet needs and market opportunities.

Neuropathic Pain

Neuropathic pain, arising from damage to the somatosensory nervous system, represents a significant area of patent activity. Conditions include diabetic neuropathy, postherpetic neuralgia, and chemotherapy-induced peripheral neuropathy.

• Targeted Therapies: Patents focus on novel molecules targeting specific ion channels (e.g., sodium, calcium), receptors (e.g., TRPV1, mu-opioid receptor modulators), and neurotransmitter systems involved in neuropathic pain signaling.
• Combination Therapies: Multiple patents explore synergistic combinations of existing or novel analgesic agents to improve efficacy and reduce reliance on single agents.
• Biologics: While less prevalent than small molecules, patent applications are emerging for biologics targeting neuroinflammation and nerve damage associated with neuropathic pain.

Inflammatory Pain

Pain associated with inflammatory conditions, such as osteoarthritis, rheumatoid arthritis, and inflammatory bowel disease, is another major focus of analgesic patenting.

• NSAIDs and Derivatives: Continuous innovation in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) focuses on improved safety profiles (e.g., COX-2 selective inhibitors with reduced gastrointestinal side effects) and novel delivery systems.
• Biologics Targeting Inflammatory Pathways: Patents for monoclonal antibodies and other biologics that inhibit pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) are numerous. These target the underlying inflammation contributing to pain.
• Small Molecules Modulating Inflammatory Mediators: Research and patenting efforts are directed towards small molecules that inhibit key enzymes or signaling pathways in inflammation, such as JAK inhibitors and PDE4 inhibitors.

Postoperative Pain Management

Patents in this area aim to provide effective and safe pain relief following surgical procedures, often seeking alternatives to traditional opioids.

• Novel Opioid Receptor Modulators: Development of peripherally acting mu-opioid receptor agonists (PAMORA) to reduce central nervous system side effects and abuse potential.
• Local Anesthetics and Nerve Blocks: Patents for new formulations of local anesthetics with extended duration of action, improved safety, and targeted delivery for nerve blocks.
• Multimodal Analgesia Approaches: Patents covering fixed-dose combinations or administration protocols that combine different classes of analgesics (e.g., NSAIDs, acetaminophen, gabapentinoids) to achieve additive or synergistic pain relief.

Chronic Pain Syndromes

Broader patents address various chronic pain conditions, including fibromyalgia, chronic low back pain, and migraines.

• Cannabinoid-Based Therapies: Patents explore the use of cannabinoids and their synthetic analogs for their analgesic and anti-inflammatory properties, often focusing on specific receptor interactions.
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Selective Serotonin Reuptake Inhibitors (SSRIs): While primarily antidepressants, patents also cover their use as analgesics for chronic pain conditions.
• Novel Targets: Emerging patent activity targets less explored pathways, including purinergic signaling, endogenous opioid systems, and neurotrophic factors.

What is the Patent Expiration Landscape for Key Analgesic Classes?

Understanding patent expiry is critical for assessing market exclusivity, generic competition, and opportunities for new product launches.

Opioid Analgesics (Traditional)

The patent landscape for older, scheduled opioid analgesics is largely expired, allowing for widespread generic availability.

• Morphine, Codeine, Oxycodone: Patents for these foundational opioids expired decades ago.
• Extended-Release Formulations: Some patents for specific extended-release formulations of these opioids may still be active, offering limited market exclusivity for branded products. For example, original extended-release oxycodone patents (e.g., OxyContin) have long expired, paving the way for generic versions.

Non-Opioid Analgesics (NSAIDs, Acetaminophen)

Patents for the active pharmaceutical ingredients (APIs) of most common NSAIDs and acetaminophen have expired.

• Ibuprofen, Naproxen, Diclofenac: Generic availability is standard.
• Acetaminophen: Patent expiry is long past.
• Novel Formulations and Combinations: Current patent activity for these drug classes primarily revolves around novel delivery systems (e.g., transdermal patches, improved oral absorption), fixed-dose combinations with other analgesics, or specific indications.

Novel Non-Opioid Analgesics (Post-2000 Era)

This category sees more recent patent filings and expirations impacting current and future market exclusivity.

• COX-2 Inhibitors (e.g., Celecoxib): While the original patents for drugs like Celebrex (celecoxib) have expired, formulation patents or method-of-use patents may still offer some protection. The primary patent for Celecoxib expired around 2018-2019 in major markets.
• Gabapentinoids (e.g., Pregabalin, Gabapentin): The patent for Lyrica (pregabalin) has expired in major markets, leading to significant generic competition. Gabapentin’s patents are considerably older.
• SNRIs for Pain (e.g., Duloxetine, Venlafaxine): Patents for the original APIs of these drugs have expired. Market exclusivity may be maintained through formulation patents or by their primary designation as antidepressants.

Emerging Analgesic Targets (Recent Filings)

For novel targets and compounds in development, patent lifecycles are much longer, typically extending 20 years from the filing date, with potential for patent term extensions.

• Trigeminal Pathway Modulators: Compounds targeting specific receptors involved in migraine or cluster headaches.
• Cannabinoid Receptor Agonists/Antagonists: Patents for synthetic cannabinoids and their specific receptor interactions are recent, with lifecycles extending into the 2030s and beyond.
• Peptide and Protein Therapeutics: Patents for new biologics targeting pain pathways are generally recent, with patent terms extending well into the future.

What are the Key Trends Shaping the Analgesic Patent Landscape?

Several overarching trends are driving innovation and patenting activity in the analgesic space.

The Opioid Crisis and Regulatory Impact

The ongoing opioid crisis has profoundly impacted the analgesic market and patent strategies.

• Shift Away from Opioids: Regulatory scrutiny and public health concerns have spurred a move towards non-opioid pain management. This has led to increased R&D investment and patent filings for alternative analgesic classes.
• Abuse Deterrent Formulations (ADFs): Patents for ADFs designed to prevent crushing, snorting, or injecting opioids have been significant. However, the efficacy and long-term impact of these technologies are still debated.
• Regulation of Controlled Substances: The stringent regulatory environment for controlled substances influences the attractiveness of developing new opioid-based analgesics, even those with potentially improved safety profiles.

Focus on Non-Addictive and Non-Opioid Alternatives

The demand for pain relief without the risk of addiction or significant side effects is a primary driver of R&D and patenting.

• Targeting Novel Pathways: Patent filings demonstrate a clear emphasis on understanding and modulating pain pathways beyond the opioid receptors, including ion channels, inflammatory mediators, and neuropeptides.
• Cannabinoids and Psychedelics: While regulatory hurdles remain, there is increasing patent activity around the therapeutic use of cannabinoids and certain psychedelic compounds for chronic and refractory pain.
• Topical and Localized Delivery Systems: Patents for advanced topical formulations and localized delivery devices (e.g., injectable gels, iontophoresis) aim to provide targeted pain relief with minimal systemic exposure and reduced side effects.

Personalized and Precision Medicine

The application of personalized medicine principles is emerging in pain management.

• Genomic and Biomarker-Based Therapies: Patents may cover diagnostic methods linked to predicting response to specific analgesics based on a patient's genetic makeup or specific pain biomarkers.
• Patient-Specific Drug Formulations: While still nascent, R&D is exploring the potential for customized drug formulations tailored to individual patient needs.

Multimodal Pain Management Strategies

Patents are increasingly focused on combinations of therapies that target pain through multiple mechanisms.

• Fixed-Dose Combinations: Development of single pills combining different classes of analgesics (e.g., an NSAID with a gabapentinoid, or an analgesic with a muscle relaxant) to improve efficacy and patient compliance.
• Co-Development of Drugs and Devices: Patents may cover the combined use of novel analgesic drugs with specific medical devices designed for targeted delivery or pain modulation.

Advancements in Drug Delivery Systems

Improved drug delivery is crucial for enhancing efficacy, reducing side effects, and improving patient compliance.

• Long-Acting Injectables: Patents for sustained-release injectable formulations that provide prolonged pain relief with fewer administrations.
• Transdermal and Transmucosal Patches: Innovations in patch technology for more efficient and controlled delivery of analgesics.
• Nanotechnology-Based Delivery: Emerging patent activity explores using nanoparticles for targeted drug delivery to pain sites, potentially improving efficacy and reducing systemic toxicity.

What are the Implications for R&D and Investment?

The current patent landscape and market trends present both opportunities and challenges for R&D and investment in the analgesic sector.

R&D Strategy Considerations

• Diversification Beyond Opioids: Companies should prioritize R&D programs focusing on non-opioid mechanisms and multimodal pain management to align with market demand and regulatory shifts.
• Neuropathic and Inflammatory Pain Focus: These areas continue to represent significant unmet needs and fertile ground for patentable innovation.
• Leveraging Non-Traditional Agents: Further exploration of cannabinoids and other novel therapeutic modalities, while navigating regulatory complexities, could yield breakthrough treatments.
• Delivery System Innovation: Investment in advanced drug delivery systems can provide a competitive edge, extending the lifecycle of existing APIs or enhancing the profile of new chemical entities.
• Biomarker Development: Investing in the development of pain biomarkers could enable the creation of more targeted and effective therapies, supporting personalized medicine approaches.

Investment Opportunities

• Emerging Biotech and Pharma Companies: Companies with robust patent portfolios in novel non-opioid analgesics, particularly those targeting neuropathic or inflammatory pain, present attractive investment prospects.
• Specialty Pharma with Repurposing Platforms: Companies that identify new indications for existing drugs, especially those with strong patent protection for method-of-use, can offer value.
• Drug Delivery Technology Developers: Companies specializing in advanced drug delivery platforms that improve safety, efficacy, or patient compliance for analgesics are key investment targets.
• Companies Developing ADFs or Abuse-Resistant Formulations: While controversial, innovative solutions addressing the abuse potential of analgesics may find a market, albeit with significant regulatory scrutiny.

Challenges and Risks

• Regulatory Uncertainty: Evolving regulations surrounding controlled substances and the approval pathways for novel pain medications can pose significant risks.
• Clinical Trial Complexity: Demonstrating efficacy and safety in pain trials, especially for chronic conditions, can be challenging and costly.
• Market Access and Reimbursement: Gaining favorable market access and reimbursement for novel analgesics, particularly those that are expensive, requires robust clinical and economic evidence.
• Generic Erosion: The rapid entry of generics for off-patent drugs necessitates a focus on truly novel compounds or significant improvements in formulations to maintain market share.

Key Takeaways

The analgesic patent landscape is characterized by a decisive shift away from traditional opioids towards non-opioid alternatives driven by the opioid crisis and a growing demand for safer pain management. Innovation is concentrated in areas such as neuropathic and inflammatory pain, with significant patent activity in novel targets, multimodal therapies, and advanced drug delivery systems. For R&D and investment, a strategic focus on non-addictive pain relief, personalized medicine approaches, and leveraging the intellectual property protection of novel formulations and targets is paramount for future success.

Frequently Asked Questions

1. What is the primary driver for new patent filings in the analgesic space? The primary driver is the need for non-addictive and non-opioid pain management alternatives, fueled by the ongoing opioid crisis and increasing regulatory scrutiny.

2. Are there still patents for common over-the-counter analgesics like ibuprofen? Patents for the active pharmaceutical ingredients (APIs) of most common over-the-counter analgesics such as ibuprofen, naproxen, and acetaminophen have long expired. Current patent activity for these agents focuses on novel formulations, delivery systems, or specific combination therapies.

3. What is the typical patent term for a newly developed analgesic drug? A newly developed analgesic drug typically receives a patent term of 20 years from the filing date. This can be extended through mechanisms like Patent Term Extension (PTE) in the U.S. or Supplementary Protection Certificates (SPCs) in Europe, to compensate for regulatory review delays.

4. How does the trend towards personalized medicine affect analgesic patenting? Personalized medicine is leading to patent filings for diagnostic tools (e.g., genetic tests, biomarkers) that predict a patient's response to specific analgesics, as well as for therapies designed to target patient subpopulations with specific genetic profiles or pain mechanisms.

5. What is the role of Abuse Deterrent Formulations (ADFs) in current patent strategies? Patents for ADFs are designed to prevent the misuse or abuse of opioid analgesics. While they have been a significant area of patenting, their market impact and ultimate success are subject to ongoing evaluation and regulatory assessment.

---

Citations

[1] U.S. National Library of Medicine. (n.d.). Medical Subject Headings: Analgesics. Retrieved from https://www.nlm.nih.gov/mesh/meshhome.html (Note: Specific MeSH term details are accessed through the NLM website; direct link to a PDF or specific entry can be volatile).

[2] U.S. Food and Drug Administration. (n.d.). Controlled Substance Act. Retrieved from https://www.dea.gov/controlled-substances-act

[3] European Medicines Agency. (n.d.). Supplementary Protection Certificates (SPCs). Retrieved from https://www.ema.europa.eu/en/medicines/human/spcs

[4] U.S. Patent and Trademark Office. (n.d.). Patent Term Adjustment and Patent Term Extension. Retrieved from https://www.uspto.gov/patents/laws/patent-term-adjustment-and-patent-term-extension

[5] (General knowledge of drug patent expiry timelines and market dynamics derived from industry analysis and public domain information on major drug lifecycles, such as those provided by market research firms and financial news outlets covering the pharmaceutical sector).